Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic

Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19 are discussed. A literature search in Google Scholar, Scopus, PubMed and clinicaltrials.gov for...

Full description

Saved in:
Bibliographic Details
Published in:Future microbiology 2022-03, Vol.17 (5), p.377-391
Main Authors: Khiali, Sajad, Khani, Elnaz, B Rouy, Samineh, Entezari-Maleki, Taher
Format: Article
Language:English
Subjects:
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
COVID-19
COVID-19 - drug therapy
Cytidine - analogs & derivatives
direct-acting antivirals
Humans
Hydroxylamines
MK-4482
molnupiravir
Pandemics
Review
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19 are discussed. A literature search in Google Scholar, Scopus, PubMed and clinicaltrials.gov for the relevant articles regarding the pharmacokinetics, pharmacodynamics and clinical trials of molnupiravir in the management of COVID-19 is conducted. Most of the preclinical studies and available clinical trials showed a favorable short-term safety profile of molnupiravir; however, given its possible genotoxic effects, further trials are required to confirm the long-term efficacy and safety of molnupiravir in patients with COVID-19.
ISSN:1746-0913
1746-0921
DOI:10.2217/fmb-2021-0252